Comparative Pharmacology
Head-to-head clinical analysis: ALUNBRIG versus TEPMETKO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALUNBRIG versus TEPMETKO.
ALUNBRIG vs TEPMETKO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alunbrig (brigatinib) is a tyrosine kinase inhibitor that targets ALK and ROS1. It inhibits autophosphorylation of ALK and ALK-mediated activation of downstream signaling proteins STAT3, AKT, ERK1/2, and PLCγ in ALK-dependent tumor cells.
Tepotinib is a highly selective, ATP-competitive inhibitor of the mesenchymal-epithelial transition (MET) receptor tyrosine kinase, including the MET exon 14 skipping variant. It inhibits MET phosphorylation and downstream signaling pathways, thereby reducing tumor cell proliferation and migration.
90 mg orally once daily for first 7 days, then increase to 180 mg orally once daily
450 mg orally once daily with food.
None Documented
None Documented
Terminal half-life approximately 25 hours. Supports once-daily dosing; steady state achieved in ~5 days.
Terminal elimination half-life approximately 12-15 hours in patients, supporting twice-daily dosing.
Primarily hepatic metabolism (CYP3A4); 65% fecal (unchanged and metabolites), 25% renal (1% unchanged). Biliary excretion contributes to fecal elimination.
Primarily fecal (≥80% of absorbed dose), with renal excretion accounting for <5% as unchanged drug.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor